Bio Pharma Dive

MARCH 31, 2025

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Gene Therapy 315

Gene Therapy Gene Regulation 315

Pharmaceutical Technology

MARCH 31, 2025

The funding is set to accelerate the development of Isomorphics AI drug design engine and advance clinical programmes.

Engineer 200

Engineer Drugs Development 200

Bio Pharma Dive

MARCH 31, 2025

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews vaccines, resigned on Friday.

Vaccine 250

Vaccine Vaccination 250

Pharmaceutical Technology

MARCH 31, 2025

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic investment climate.

Drugs 147

Drugs 147

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Bio Pharma Dive

MARCH 31, 2025

Accelerate biomarker research with high-quality, expert-curated data to drive precision medicine.

Medicine 246

Medicine Research 246

Pharmaceutical Technology

MARCH 31, 2025

Based on the Phase II data, Imbria Pharmaceuticals inerafaxstat could complement existing treatments rather than replace them.

130

130

Pharmaceutical Technology

MARCH 31, 2025

The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of overpricing.

Containment 130

Containment Drugs Marketing 130

Bio Pharma Dive

MARCH 31, 2025

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and predict molecular structures.

Drugs 143

Drugs Development 143

Pharmaceutical Technology

MARCH 31, 2025

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the treatment life cycle.

Gene Therapy 130

Gene Therapy Gene 130

pharmaphorum

MARCH 31, 2025

The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug

Drugs 98

Drugs 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharmaceutical Technology

MARCH 31, 2025

Despite a haemophilia market bustling with rivals, Qfitlias broad label and favourable dosing regimen could give it an upper hand.

Marketing 130

Marketing 130

pharmaphorum

MARCH 31, 2025

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial

Trials 78

Trials 78

Pharmaceutical Technology

MARCH 31, 2025

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Development 130

Development Trials 130

pharmaphorum

MARCH 31, 2025

Industry organisations are alarmed by the resignation of senior FDA official Peter Marks, citing "misinformation and lies" by HHS Secretary Kennedy

76

76

Advertisement

Clinical Supply

Pharmaceutical Technology

MARCH 31, 2025

Completed biopharma IPOs that raised more than $100 million witnessed an almost twofold increase during 2024.

130

130

pharmaphorum

MARCH 31, 2025

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine and advance its pipeline.

Engineer 65

Engineer Drugs 65

Pharmaceutical Commerce

MARCH 31, 2025

Jen Butler, chief commercial officer, Pleio, discusses the importance of balancing technology and personalization in patient support.

52

52

pharmaphorum

MARCH 31, 2025

Watch the exclusive interview with Brian Hilberdink, the new head of Boehringer US, as he discusses GLP-1s, DtX, and more in this insightful video discussion.

59

59

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Commerce

MARCH 31, 2025

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

52

52

pharmaphorum

MARCH 31, 2025

Accelerating Breakthroughs in Immunodermatology Drug Development Sara.

Development 52

Development Drugs 52

Pharmaceutical Commerce

MARCH 31, 2025

The latest news for pharma industry insiders.

52

52

pharmaphorum

MARCH 31, 2025

The Home of Accelerating Microbiome R&D Sara.

52

52

Advertisement

Clinical Supply

Pharmaceutical Technology

MARCH 31, 2025

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic syndrome.

130

130

pharmaphorum

MARCH 31, 2025

At Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh sat down with Dr Sebastian Vaughn, CEO of Phytome Life Sciences, for an en plein air and explorative conversation around the topic of mental health, live onsite at The Eden Project in Cornwall, following the Adelphi sponsored panel, Revolutionary Thinking for Mental Health.

Life Science 52

Life Science 52

FDA Law Blog

MARCH 31, 2025

By Steven J. Gonzalez On March 31, 2025, U.S. District Judge Sean D. Jordan ordered that FDAs Laboratory Developed Tests (LDT) Final Rule be vacated and set aside, in its entirety. That Rule sought to codify FDAs view that LDTs are medical devices subject to FDA regulation under the Food, Drug, and Cosmetic Act (FDCA) and then phase out, over a four-year period, FDAs purported policy of enforcement discretion for such tests.

Development 111

Development Cosmetics Regulation In-Vitro 111

pharmaphorum

MARCH 31, 2025

Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial

Drugs 45

Drugs Trials 45

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Drug Channels

MARCH 31, 2025

Threes still company in the world of pharmacy benefit managers. For 2024, nearly 80% of all equivalent prescription claims were processed by three familiar companies: the CVS Caremark business of CVS Health, the Express Scripts business of Cigna, and the Optum Rx business of UnitedHealth Group. The names havent changed, but shifting relationships and contract shakeups have altered the plot, with Express Scripts stepping into a new lead role.

Pharmacy 98

Pharmacy Marketing Development Drugs 98

XTalks

MARCH 31, 2025

The FDA has granted De Novo authorization to the Visby Medical Womens Sexual Health Test. The PCR-based test detects three of the most common and curable STIs: chlamydia, gonorrhea and trichomoniasis. The single-use test, designed for women and regardless of symptom presence, delivers results in approximately 30 minutes. It includes a self-collected vaginal swab and a powered testing device.

In-Vitro 85

In-Vitro Hormones FDA Approval Marketing 85

Sciensano

MARCH 31, 2025

Event type: closed meeting Audience: health professionals Description: You are kindly invited to the IQED -Foot Information Meeting of audit 8, organised by Sciensano in collaboration with the Group of Experts IQED -Foot, on behalf of the National Institute of Health and Disability Insurance ( NIHDI ). Programme 18.00 19.30 : Registration and walking dinner 19.30-22.15 : Presentations and discussion 22.30 : End Registration Please register before 10 June using this form Contact If you have any

52

52

XTalks

MARCH 31, 2025

Fresenius Kabi received FDA approval for its Prolia and Xgeva biosimilars, Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht), respectively. The FDA granted authorization to the denosumab biosimilars for all indications corresponding to their reference products. The agency approved Conexxence for use in adult patients at high risk for fractures.

FDA Approval 59

FDA Approval Production Development Antibody 59

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research